Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 80 years~* Patients with signs and/or symptoms of heart failure NYHA II, III or IV, with echocardiographic diagnosis of HFrEF..~* Moderate impairment of renal functions, assessed by measuring serum creatinine levels then estimating the glomerular filtration rate (eGFR) by Cockroft-Gold equation to be (60-40 ml/min/m2).~Exclusion Criteria:~* Refusal to participate in the study.~* Known allergy to enalapril/telmisartan components.~* Pregnant and lactating ladies.~* Severe renal impairment defined as eGFR\<30ml/min/m2 at time of enrollment to the study.~* Known cases of bilateral severe renal artery stenosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Telmisartan (Type: ACTIVE_COMPARATOR): Telmisartan (20 up to 80mg) for RAAS inhibition, as part of their heart failure therapy.
- Enalapril (Type: NO_INTERVENTION): Enalapril (2.5 up to 20mg ) for RAAS inhibition, as part of their heart failure therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).